Reuters logo
BRIEF-Immunogen announces investigational new drug application for IMGN632 for hematological malignancies is active
2017年10月16日 / 中午12点17分 / 1 个月前

BRIEF-Immunogen announces investigational new drug application for IMGN632 for hematological malignancies is active

Oct 16 (Reuters) - Immunogen Inc:

* Immunogen announces investigational new drug application for IMGN632 for hematological malignancies is active

* Immunogen - ‍FDA completed safety review of investigational new drug application for IMGN632 in patients with CD123-positive hematological malignancies​

* Immunogen Inc - ‍filed in mid-September, IND is now in effect and Immunogen plans to open a Phase 1 study to enrollment before end of year​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below